Pro Bono Bio wraps round of hemophilia trials; Eaton develops first non-hormonal menopause patch;

> Pro Bono Bio has completed its first series of trials of subcutaneous treatments for hemophilia, showing that the therapies improve blood clotting for extended periods. These would make self-administration of blood-clotting factors simpler and reduce the need for intravenous infusions, potentially improving compliance and cutting healthcare costs. Press release

> Eaton Scientific Systems is developing a transdermal patch to deliver homatropine for non-hormonal treatment of hot flashes in menopausal women. According to the company, this will be the world's first prescription non-hormonal transdermal treatment for hot flashes. Press release

> India-based Panacea Biotec has tied up with drug delivery company Osmotica Pharmaceutical to create generic and branded formulations for global markets. Article

> The African University of Science and Technology (AUST) is developing a nanoparticle-delivered formulation of a chemotherapeutic derived from bacteria, prodigosene, as a cancer drug, and animal studies are planned for next year. Article

> Neuralstem has licensed its spinal cord delivery platform and floating cannula, for delivering therapeutic agents to the spinal cord, to Q Therapeutics. Financial terms were not disclosed. Press release

> OncoSec Medical has licensed electroporation technology from the University of South Florida Research Foundation (USFRF). Article

> Indian company Opto Eurocor Healthcare has launched E-MAGIC, a sirolimus drug-eluting stent, in the domestic market. Article

> NIH researchers are tackling the blood-brain barrier by switching off the gatekeeper molecule P-glycoprotein. Press release | Abstract

And Finally… West Pharmaceutical Services introduces its B.safe syringe safety system, which protects against needlestick injury when using a prefilled syringe. Article

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.